Why Inhibrx Biosciences (INBX) Stock Is Down Today

By: Quiver PriceTracker

Posted: 3 days, 10 hours ago / Sept. 8, 2026 6:37 p.m. UTC

INBX

Inhibrx Biosciences (INBX) is down 6.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to investor digestion of new Phase 2 data for INBRX-106 in head and neck cancer. While the company posted encouraging efficacy figures, the selloff may reflect a sell-the-news reaction and some caution that the readout was still interim, based on a limited evaluable population, and now points to an added expansion cohort before potential regulatory discussions.

Details:

Inhibrx announced primary endpoint results from the randomized Phase 2 portion of its HexAgon study evaluating INBRX-106 plus pembrolizumab against pembrolizumab alone in first-line PD-L1 positive recurrent or metastatic HNSCC.

The company said confirmed objective response rate was 48.3% for the combination arm versus 26.5% for the control arm, while interim median progression-free survival was 9.6 months versus 4.9 months.

The dataset included 68 randomized patients, with 63 evaluable for the primary endpoint analysis, which may have kept some investors cautious despite the apparent clinical benefit.

Inhibrx said it plans to expand the Phase 2 study by about 50 additional HPV-positive patients, then align with the FDA and later start the Phase 3 portion, suggesting the path to a potential approval is still not immediate.

Sources:

Inhibrx Investor Relations, SEC, Yahoo Finance

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$INBX Hedge Fund Activity

We have seen 102 institutional investors add shares of $INBX stock to their portfolio, and 80 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BANK OF AMERICA CORP /DE/ added 808,458 shares (+2473.6%) to their portfolio in Q2 2026, for an estimated $76,601,395
SCHONFELD STRATEGIC ADVISORS LLC added 442,759 shares (+173.7%) to their portfolio in Q2 2026, for an estimated $41,951,415
CALIGAN PARTNERS LP removed 323,565 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $21,753,274
VIKING GLOBAL INVESTORS LP removed 313,776 shares (-21.8%) from their portfolio in Q2 2026, for an estimated $29,730,276
PARKMAN HEALTHCARE PARTNERS LLC added 256,950 shares (+inf%) to their portfolio in Q2 2026, for an estimated $24,346,012
GOLDMAN SACHS GROUP INC added 243,102 shares (+255.7%) to their portfolio in Q2 2026, for an estimated $23,033,914
MILLENNIUM MANAGEMENT LLC removed 180,660 shares (-55.1%) from their portfolio in Q2 2026, for an estimated $17,117,535

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.